Gastroenterology and Intestinal Disorders
Mikrobiomik Healthcare Company S.L. focuses on clinical research in gastroenterology, with activity centred on recurrent diverticulitis and related intestinal inflammation. Its trials reflect interest in conditions involving the colon, digestive tract, and microbiota-based therapies.
- Recurrent diverticulitis
- Intestinal microbiota
- Digestive system disease
The sponsor’s work in this area is directed toward treatment options for patients with repeated episodes of diverticular disease and associated gastrointestinal burden.
Hepatology and Liver Disease
The company also funds research in hepatology, particularly for non-alcoholic steatohepatitis, a chronic metabolic liver disease marked by inflammation and liver injury. This area places emphasis on liver-related outcomes and disease modification.
- Non-alcoholic steatohepatitis
- Liver inflammation
- Metabolic liver disorder
Its clinical portfolio includes therapies intended to address liver health in patients with steatohepatitis and related metabolic dysfunction.
Microbiota-Based Therapeutics
A central theme in the sponsor’s research is the use of faecal microbiota transfer and intestinal microbiota capsules as therapeutic approaches. This reflects a strong interest in microbiome modulation for both gastrointestinal and liver-related conditions.
- Faecal microbiota transfer
- Microbiome modulation
- Capsule-based microbiota therapy
Research activity in this domain links microbial restoration strategies with disease management in disorders of the gut-liver axis.
Gut-Liver Axis Research
The sponsor’s clinical interests extend across the gut-liver axis, where interactions between the intestinal microbiome and hepatic function are relevant to both diverticular disease and steatohepatitis. This connects digestive and liver medicine through microbiome-oriented intervention.
- Gut-liver axis
- Intestinal microbiome
- Hepatic function
The funded studies indicate sustained involvement in therapeutic areas where microbial balance is considered important for gastrointestinal and liver outcomes.
